Life Sciences
Tempus Forms Multi-omics Collaboration With Actuate Therapeutics
What You Should Know: – Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with…
What You Should Know:
– Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a single method alone.
– This multi-omics approach is being used by Actuate Therapeutics in support of their Phase 1/2 oncology study of elraglusib, a GSK-3β inhibitor, which includes a randomized study in patients with metastatic pancreatic cancer.
– The drug has shown clinical benefit for multiple advanced cancers. Tempus’ diagnostic technology and multimodal (i.e., DNA, RNA, and imaging) data will support the discovery and validation of novel targets and biomarker profiles that will help determine which patients may respond better to the drug – demonstrating a new way in which precision medicine can be incorporated in clinical development.
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….